# AC Immune SA share price today (AC Immune SA, ACIU)

> AC Immune SA's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ACIU · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/aciu

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $2.29 (−30.6% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026): ₹0.0 B
- ROE: −157%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the AC Immune SA share price today? AC Immune SA's share price was $2.29 at the close on 4 November 2026. That is 15.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $4, and at that close it sat 7% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 6 weeks in a row. Over the last 1 year the share price moved +12% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does AC Immune SA pay? AC Immune SA pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is AC Immune SA on? AC Immune SA is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is AC Immune SA profitable? AC Immune SA earned ₹0.0 B of net profit in the Jun 2026 quarter. The full FY25 year was a loss of ₹0.1 B. That is 12.4% of the quarter's revenue. The same quarter a year earlier lost ₹0.02 B. 10 of the last 12 reported quarters were loss-making. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does AC Immune SA make, and is it growing? AC Immune SA reported ₹0.0 B of revenue in the Jun 2026 quarter, +1,057.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown −3.2% a year on average. The last full year, FY25, came in at ₹0.0 B. The last four reported quarters add to ₹0.0 B. FY25 revenue was ₹0.0 B, −86.9% on the year before. Recent pace: the last four quarters grew +225.9% on average, against −3.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −39.5%, against −5.1% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does AC Immune SA keep? AC Immune SA's sales have fallen to very little: FY25 revenue was ₹0.0 B, against ₹0.0 B in FY24. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is AC Immune SA's profit turning into cash? AC Immune SA's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.1 B of cash, against −₹0.1 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.1 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does AC Immune SA's cash go? AC Immune SA does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is AC Immune SA's P/E ratio, and how does it compare with its own history? AC Immune SA has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the AC Immune SA business getting better or worse? AC Immune SA's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does AC Immune SA earn on its capital? AC Immune SA earned a ROE of −157% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −48%, a number that says nothing useful about the business. ## Does AC Immune SA have too much debt? AC Immune SA has total debt of ₹0.0 B against shareholder equity of ₹0.0 B as of Jun 2026, so its debt is 0.12× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.10 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the AC Immune SA shareholding pattern? We have no ownership or short-position figures for AC Immune SA, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 16.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is AC Immune SA from balance-sheet trouble? For AC Immune SA, the Z-score is −3.94. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −3.94 is inside the danger zone, so the balance sheet is a real risk. ## How does AC Immune SA rank in its industry? There is no score against its industry: AC Immune SA is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is AC Immune SA compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to AC Immune SA in size? AC Immune SA is the 187th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Abeona Therapeutics Inc., Camp4 Therapeutics Corporation and Vanda Pharmaceuticals Inc. Just below it: Evommune, Inc., InflaRx N.V. and Protalix BioTherapeutics, Inc. ### Biotechnology companies close in size

1. [Abeona Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/abeo) $241 million
2. [Camp4 Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/camp) $235 million
3. [Vanda Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/vnda) $235 million
4. AC Immune SA $228 million
5. [Evommune, Inc.](https://www.sectoralpha.in/us/stocks/evmn) $219 million
6. [InflaRx N.V.](https://www.sectoralpha.in/us/stocks/ifrx) $218 million
7. [Protalix BioTherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/plx) $217 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [SuperX AI Technology Limited](https://www.sectoralpha.in/us/stocks/supx) $208 million · Software - Infrastructure
2. [Superior Group of Companies, Inc.](https://www.sectoralpha.in/us/stocks/sgc) $208 million · Apparel Manufacturing
3. AC Immune SA $208 million
4. [Chicago Atlantic BDC, Inc.](https://www.sectoralpha.in/us/stocks/lien) $208 million · Asset Management
5. [Firy Inc.](https://www.sectoralpha.in/us/stocks/firy) $208 million · Electronic Gaming & Multimedia

## What else do people ask about AC Immune SA? ### What were AC Immune SA's latest quarterly results? AC Immune SA reported revenue of ₹0.0 B and net profit of ₹0.0 B for the Jun 2026 quarter. The operating margin was 7.9%, 1,492.5 percentage points higher than a year earlier (as of 4 November 2026). ### What is AC Immune SA's profit? AC Immune SA earned ₹0.0 B of net profit in the Jun 2026 quarter. Full-year FY25 profit was −₹0.1 B. The operating margin was 7.9% in the latest quarter (as of 4 November 2026). ### What is AC Immune SA's market cap? AC Immune SA's market capitalisation is $228 M at a stock price of $2.29. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is AC Immune SA performing? AC Immune SA's latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will AC Immune SA's stock price go up? This page does not forecast AC Immune SA's stock price. What it shows instead: the stock price is $2.29. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does AC Immune SA have too much debt? No, AC Immune SA has little debt: its debt is 0.14× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### What could break the AC Immune SA story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is AC Immune SA a stock worth studying right now? What the numbers show: AC Immune SA's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.